Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
about
Cellular immunotherapy for pediatric solid tumorsNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineIdentification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.Engineered T cells for cancer treatmentLong-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphomaHLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in ChinaAdoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.The molecular pathogenesis of Hodgkin lymphoma.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vectorHuman Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferT cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?Adoptive cellular immunotherapy for childhood malignancies.Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agentDecreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinomaEnhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy.Immunotherapy targeting EBV-expressing lymphoproliferative diseasesCytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.The pathological roles of BART miRNAs in nasopharyngeal carcinoma.Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis.Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination.CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.Use of CD107-based cell sorting ex vivo to enrich subdominant CD8+ T cells in culture.Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopesAdoptive cell therapy against EBV-related malignancies: a survey of clinical resultsRole of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
P2860
Q27014912-91C18DC2-08F2-4BBB-9101-E45154303125Q28749468-02BB4A28-0628-43D4-A601-C18FC5C7A8C2Q33303005-BB786A35-B5A5-4F1F-BDDB-CA8DC7211572Q33578792-A6B44C93-8DE1-486C-8D45-6157907EE2A2Q33634455-E1D83711-FDEB-4C61-9C11-6D400E2DAAFDQ33713932-C2A86540-1EC7-4B7D-8F10-2C0010FD4FFEQ33778708-D8A3297E-87BD-405C-997E-3EF2E734903DQ34166497-716FAD5D-08E6-4884-9C0E-5223FC07705EQ34242449-D1D63C30-8C26-4F19-93A5-C406FA2F90C7Q34626576-EDC61BEC-1AB9-4A42-A976-6DFBB933EBD8Q35068768-E0573539-FD7C-4473-B39B-D278703431A6Q35222179-0CED43EF-579D-4733-A726-BA1974CC2CABQ35238310-2F8937DF-CAD4-49FA-BECF-F13CABA078D6Q35684896-FE88DD8D-291D-4FF4-B0AE-FAF5C1C7973CQ36059593-E4D2A5C6-9B28-442E-ABAB-0D415D87A347Q36821993-C0320BD9-A715-41AC-A844-F1952D0036F6Q37008216-01EA1EE8-90C7-4392-A25B-C803C21167C4Q37101134-33D20A69-3610-449F-82D4-05F955034F3FQ37117769-F515642E-1CE0-44E7-AF36-2866C40D644DQ37129671-69A06923-A7A5-44E1-A52C-A6F2C63CDBE9Q37225034-F7C66D73-BCA9-4226-B612-CA0B5619C653Q37268305-C75B2EB2-3128-4C62-988E-03921D970187Q37414729-5618909B-A36B-405D-B6C7-77731CE1132FQ37995110-2BD5BDE1-AA51-4231-BAA2-F83B798ECD50Q38759383-234E30F4-49FB-4CBA-8ACA-019318CC70A7Q38803361-A1A97982-E40B-4AFA-A026-E6C7E87CE242Q40703339-6E1598A4-780B-4A08-B877-8C952D56044AQ42632595-3202226E-6C39-404A-98CC-0F4F73A43491Q43238571-FB106E74-3A13-4467-A8BA-187A2D96A3F4Q45029775-5E78B56A-666E-4E79-9D75-103C2CDBFE5BQ45077858-59E37926-ED98-496F-9AA0-F4781AF9B88EQ45368108-00EF6C68-F7A8-4932-A12C-77B8DFB5562EQ45398515-9AEDEB86-A419-4DC8-9D87-6101C67AF61BQ47114749-C8A89718-6525-43DF-AD09-27BA783270BDQ47549907-B80B831B-B69B-414E-AC97-570452FF274BQ47728296-EA90C1F5-17CC-462B-8C1A-7C6B58151AA1Q53547204-35DC2D32-7DDB-4AC9-A49C-33444874EF74Q57056118-243FEE2F-3086-481E-A3C5-F0A55D52D7E2Q57056125-74345D99-2434-4433-BA43-BA1382D43AC5Q57176933-39C7E295-15F7-418B-A8C6-157CFB2884E9
P2860
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@ast
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@en
type
label
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@ast
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@en
prefLabel
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@ast
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@en
P2093
P1476
Characterization of latent mem ...... yngeal carcinoma and lymphoma.
@en
P2093
Ann M Leen
Catherine M Bollard
Cliona M Rooney
Elizabeth L Buza
Graham Taylor
Helen E Heslop
Karin C Straathof
M Helen Huls
P304
P356
10.4049/JIMMUNOL.175.6.4137
P407
P577
2005-09-01T00:00:00Z